Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | YES1 | P07947 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 3/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487943 | 0.86 | NR1H2 (0.44) | NR1H2NR1H3INSRJAK2STAT6 | |
| SCHEMBL4690096 | 0.84 | NR1H2 (0.51) | NR1H2NR1H3INSRJAK2ABL1 | |
| SCHEMBL3487718 | 0.80 | NR1H2 (0.58) | NR1H2NR1H3INSRJAK2ABL1 | |
| SCHEMBL3487297 | 0.80 | NR1H2 (0.46) | NR1H2NR1H3INSRJAK2MAPK1 | |
| SCHEMBL4685753 | 0.80 | NR1H2 (0.41) | NR1H2NR1H3INSRJAK2ABL1 | |
| SCHEMBL3489506 | 0.79 | NAMPT (0.36) | NR1H2NR1H3MEN1MAPTKMT2A | |
| SCHEMBL3487939 | 0.79 | DGAT1 (0.42) | JAK2STAT6PLK4SMN1; SMN2MEN1 | |
| SCHEMBL4688259 | 0.78 | JAK2 (0.42) | INSRJAK2ABL1NTRK1YES1 | |
| SCHEMBL3487580 | 0.76 | NR1H2 (0.54) | NR1H2NR1H3INSRJAK2ABL1 | |
| SCHEMBL3488372 | 0.76 | NR1H2 (0.53) | NR1H2NR1H3INSRJAK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | claimed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | claimed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| EP-1838686-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | claimed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1838686-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885INSR 10/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | NR1H2 1/4885NR1H3 2/4885INSR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.